Effect of Vitamin E on Oxaliplatin‑induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial

Abstract

Background:Peripheral neuropathy is one of the most important limitations of oxaliplatin base regimen, which is the standard for the treatment of colorectal cancer. Evidence has shown that Vitamin E may be protective in chemotherapy‑induced peripheral neuropathy. The aim of thisstudy is to evaluate the effect of Vitamin E administration on prevention of oxaliplatin‑induced peripheral neuropathy in patients with colorectal cancer.Methods: This was a prospective randomized, controlled clinical trial. Patients with colorectal cancer and scheduled to receive oxaliplatin‑based regimens were enrolled in this study. Enrolled patients were randomized into two groups. The first group received Vitamin E at a dose of 400mg daily and the second group observed, until after the sixth course of the oxaliplatin regimen. For oxaliplatin‑induced peripheral neuropathy assessment, we used the symptom experience diary questionnaire that completed at baseline and after the sixth course of chemotherapy. Only patients with a score of zero at baseline were eligible for this study.Results: Thirty‑two patients were randomized to the Vitamin E group and 33 to the control group. There was no difference in the mean peripheral neuropathy score changes(after−before) between two groups, after sixth course of the oxaliplatin base regimen (mean difference [after − before] of Vitamin E group= 6.37 ± 2.85, control group= 6.57 ± 2.94; P = 0.78). Peripheral neuropathy scores were significantly increased after intervention compared with a base line in each group (P < 0.001).Conclusions:The results from this current trial demonstrate a lack of benefit for Vitamin E in preventing oxaliplatin‑induced peripheral neuropathy.Keywords: Colorectal neoplasms, oxaliplatin, peripheral nervous system diseases, Vitamin E